Serum apolipoprotein e level is not increased in Alzheimer's disease: The Rotterdam study

Neuroscience Letters

Volumn 248, Issue 1, 1998, Pages 21-24

  Slooter, Arjen J C ^a   De Knijff, Peter ^b,c   Hofman, Albert ^a   Cruts, Marc ^d   Breteler, Monique M B ^a   Van Broeckhoven, Christine ^d   Havekes, Louis M ^b,e   Van Duijn, Cornelia M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Apolipoprotein E; Atherosclerosis; Dementia; Plasma; Serum level

Indexed keywords

APOLIPOPROTEIN E;

ALBUMIN BLOOD LEVEL; ALLELE; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; DISEASE ASSOCIATION; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED;

EID: 0032557509     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00339-5     Document Type: Article

References (18)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, third edition, revised, American Psychiatric Association, Washington DC, 1987.
2. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer's disease. Mol. Brain. Res. 33:1995;174-178.
3. 3 cholesterol, apoA-I and apoA-II, and increased risk of myocardial infarction. Circulation. 85:1992;22-29.
4. Couderc R., Mahieux F., Bailleul S., Fenelon G., Mary R., Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. A case-control study, Stroke. 24:1993;661-664.
5. Duong T., Pommier E.C., Scheibel A.B. Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathol. 78:1989;429-437.
6. Galasko D., Hansen L.A., Katzman R., Wiederholt W., Masliah E., Terry R., Hill L.R., Lessin P., Thal L.J. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol. 51:1994;888-895.
7. Hofman A., Grobbee D.E., De Jong P.T.V.M., Van den Ouweland F.A. Determinants of disease and disability in the elderly: the Rotterdam elderly study. Eur. J. Epidemiol. 7:1991;403-422.
8. Hofman A., Ott A., Breteler M.M.B., Bots M.L., Slooter A.J.C., Van Harskamp F., Van Duijn C.N., Van Broeckhoven C., Grobbee D.E. Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer's disease in a population-based study: the Rotterdam study. Lancet. 349:1997;151-154.
9. Lambert J.-C., Pérez-Tur J., Dupire M.-J., Galasko D., Mann D., Amouyel P., Hardy J., Delacourte A., Chartier-Harlin M.-C. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum. Mol. Genet. 6:1997;2151-2154.
10. Linton M.F., Gish R., Hubl S.T., Butler E., Esquivel C., Bry W.I., Boyles J.K., Wardell M.R., Young S.G. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88:1991;270-281.
11. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA workgroup under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
12. Ott A., Breteler M.M.B., Van Harskamp F., Claus J.J., Van der Cammen T.J.M., Grobbee D.E., Hofman A. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study, Br.Med. J. 310:1995;970-973.
13. Skoog I., Hesse C., Fredman P., Andreasson L.-A., Palmertz B., Blennow K. Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. Arch. Neurol. 54:1997;267-272.
14. Slooter, A.J.C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M.M.B., Van Broeckhoven, C. and Van Duijn, C.M., Apolipoprotein E and dementia. Risk estimates from a population-based incidence study: the Rotterdam study, Arch. Neurol., in press.
15. Smit M., De Knijff P., Rosseneu M., Bury J., Klasen E., Frants R., Havekes L.M. Apolipoprotein E polymorphism in the Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum. Genet. 80:1988;287-292.
16. Stern Y., Brandt J., Albert M., Jacobs D.M., Liu X., Bell K., Marder K., Sano M., Albert S., Castenada C.D.-C., Bylsma F., Tycko B., Mayeux R. The absence of an apolipoprotein M4 allele is associated with a more aggressive form of Alzheimer's disease. Ann. Neurol. 41:1997;615-620.
17. Taddei K., Clarnette R., Gandy S.E., Martins R.N. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci. Lett. 223:1997;29-32.
18. Van Vlijmen B.J.M., Van't Hof H.B., Mol M.J.T.M., Van der Boom H., Van der Zee A., Frants R.R., Hofker M.H., Havekes L.M. Modulation of very low density lipoprotein production and clearance contributes to age- and gender dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J. Clin. Invest. 97:1996;1184-1192.